AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8751166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation (Sao2) after medication
Number of subjects: 74
Study 8751166 — intervention group
Group type: COMPARATOR
Intervention: Clinical response to treatment
Number of subjects: 74
Study 2048049 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 0.3 micrograms/kg
Number of subjects: 20
Study 2048049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2048049 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 20
Study 2048049 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 20
Study 6455963 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (oral treatment)
Number of subjects: 8
Study 6455963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31791396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for insomnia (CBTi) - six sessions
Number of subjects: 102
Study 31791396 — intervention group
Group type: COMPARATOR
Intervention: Sleep support group - six sessions
Number of subjects: 102
Study 31791396 — intervention group
Group type: COMPARATOR
Intervention: Audiologically based care - two sessions
Number of subjects: 102
Study 27491377 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (3 mg/kg of zinc sulfate monohydrate twice a day orally for 10 days)
Number of subjects: 0
Study 27491377 — intervention group
Group type: COMPARATOR
Intervention: Control group (antibiotics and supportive care)
Number of subjects: 0
Study 27491377 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc group
Number of subjects: 0
Study 26114468 — intervention group
Group type: EXPERIMENTAL
Intervention: Size Matters Handwriting Program for 40 sessions
Number of subjects: 207
Study 26114468 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction (Control)
Number of subjects: 207
Study 23368685 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle fractional RF plus stem cell conditioned medium
Number of subjects: 15
Study 23368685 — intervention group
Group type: COMPARATOR
Intervention: Microneedle fractional RF alone
Number of subjects: 15
Study 20971535 — intervention group
Group type: EXPERIMENTAL
Intervention: CCD (preOp(®), Nutricia, UK, 50 g carbohydrate)
Number of subjects: 10
Study 20971535 — intervention group
Group type: EXPERIMENTAL
Intervention: CCD/G (preOp(®), 36 g carbohydrate + 15 g glutamine)
Number of subjects: 10
Study 20971535 — intervention group
Group type: EXPERIMENTAL
Intervention: CCD/L (preOp(®), 36 g carbohydrate + 7 g lipid)
Number of subjects: 10
Study 20971535 — intervention group
Group type: COMPARATOR
Intervention: CCD
Number of subjects: 10
Study 20971535 — intervention group
Group type: EXPERIMENTAL
Intervention: CCD/G
Number of subjects: 10
Study 20971535 — intervention group
Group type: EXPERIMENTAL
Intervention: CCD/L
Number of subjects: 10
Study 20971535 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 10
Study 19134240 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and LC‐PUFA-containing experimental formulas
Number of subjects: 142
Study 19134240 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 142
Study 17827461 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (fluorouracil and cisplatin) combined with radiation
Number of subjects: 0
Study 17827461 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 0
Study 17827461 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytotoxic drugs or increased radiation dose
Number of subjects: 0
Study 17827461 — intervention group
Group type: EXPERIMENTAL
Intervention: Camptothecin and taxane-based regimens combined with radiation
Number of subjects: 0
Study 15182893 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 52
Study 15182893 — intervention group
Group type: COMPARATOR
Intervention: Placebo naltrexone (Control)
Number of subjects: 52
Study 11641030 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1.5 mg/kg, 6 hourly)
Number of subjects: 21
Study 11641030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9676350 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily administration of sustained release theophylline
Number of subjects: 18
Study 9676350 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily administration of sustained release theophylline
Number of subjects: 18
Study 7986180 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive oral cabergoline (maximum dose, 5 mg/d)
Number of subjects: 41
Study 7986180 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive oral cabergoline
Number of subjects: 41
Study 7986180 — intervention group
Group type: COMPARATOR
Intervention: Carbidopa and levodopa without cabergoline
Number of subjects: 41
Study 2733574 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (320 mg ferrous sulfate)
Number of subjects: 40
Study 2733574 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 40
Study 31575825 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 2 mg·kg‐1
Number of subjects: 28
Study 31575825 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 4 mg·kg‐1
Number of subjects: 28
Study 31575825 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg·kg‐1
Number of subjects: 28
Study 31575825 — intervention group
Group type: COMPARATOR
Intervention: No-placebo control
Number of subjects: 28
Study 31575825 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 28
Study 26673692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside consumption (43 mg/d)
Number of subjects: 23
Study 26673692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside consumption (43 mg/d) in patients with IBD
Number of subjects: 23
Study 25141095 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 168
Study 25141095 — intervention group
Group type: COMPARATOR
Intervention: Metal cannula
Number of subjects: 168
Study 23286660 — intervention group
Group type: EXPERIMENTAL
Intervention: Six professionally developed brochures with preconception health messages
Number of subjects: 687
Study 23286660 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 687
Study 20702513 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with Bobath techniques
Number of subjects: 48
Study 20702513 — intervention group
Group type: COMPARATOR
Intervention: Bobath techniques alone (Control)
Number of subjects: 48
Study 19565735 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined moxibustion and medicine group (n = 22)
Number of subjects: 75
Study 19565735 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine group (n = 29)
Number of subjects: 75
Study 19565735 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (n = 24)
Number of subjects: 75
Study 16505439 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a 180 mug once weekly for 24 weeks
Number of subjects: 150
Study 16505439 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a 360 mug once weekly for 24 weeks
Number of subjects: 150
Study 16505439 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a 450 mug once weekly for 24 weeks
Number of subjects: 150
Study 16505439 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a (all doses)
Number of subjects: 150
Study 14718821 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (therapy group) with physical therapy designed to strengthen calf musculature.
Number of subjects: 31
Study 14718821 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention beyond Class II compression hosiery).
Number of subjects: 31
Study 11572531 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg acetaminophen
Number of subjects: 60
Study 11572531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9484618 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 0
Study 9484618 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 0
Study 9484618 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 0
Study 9484618 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotective agents
Number of subjects: 0
Study 9484618 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG Co‐A reductase inhibitors
Number of subjects: 0
Study 7828215 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking smokers
Number of subjects: 24
Study 7828215 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent smokers
Number of subjects: 24
Study 7828215 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 24
Study 2892989 — intervention group
Group type: EXPERIMENTAL
Intervention: (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) plus calcium (1 g/day)
Number of subjects: 0
Study 2892989 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone (Control)
Number of subjects: 0
Study 29702684 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-50% N2O-O2 mixture
Number of subjects: 84
Study 29702684 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen inhalation (Control)
Number of subjects: 84
Study 26897518 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5% cream for 16 weeks
Number of subjects: 140
Study 26897518 — intervention group
Group type: COMPARATOR
Intervention: Immediate LLETZ (standard care)
Number of subjects: 140
Study 26897518 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5% cream
Number of subjects: 140
Study 26210791 — intervention group
Group type: EXPERIMENTAL
Intervention: Boric acid
Number of subjects: 240
Study 26210791 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 240
Study 23997689 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly, supervised hospital-based maintenance exercise plus home exercise for 12 months
Number of subjects: 48
Study 23997689 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised home maintenance exercise for 12 months
Number of subjects: 48
Study 21941220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (intravenous loading dose 0.5 mg/kg followed by 9 μg/kg per minute for 20 mins)
Number of subjects: 48
Study 21941220 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg orally over 2 days)
Number of subjects: 48
Study 21941220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 21941220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.006, 0.02, 0.06, and 0.2 mg/kg per minute) in rats
Number of subjects: 48
Study 21941220 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (0.127, 0.42, and 1.27 mg/kg per minute) in rats
Number of subjects: 48
Study 18816801 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing and writing movements using a pen attached to the bottom of a finger splint
Number of subjects: 21
Study 18816801 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic putty to train finger movements without exercises of drawing and writing movements
Number of subjects: 21
Study 18816801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training modalities
Number of subjects: 21
Study 18816801 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-training
Number of subjects: 21
Study 16470607 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic lamivudine (100 mg daily before and until at least 8 weeks after chemotherapy)
Number of subjects: 156
Study 12857352 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitized M-mode recordings
Number of subjects: 0
Study 12857352 — intervention group
Group type: COMPARATOR
Intervention: M-mode strip chart recordings
Number of subjects: 0
Study 10635654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg administered at 8 a.m.
Number of subjects: 30
Study 10635654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg administered at 14.00 (2 p.m.)
Number of subjects: 30
Study 10635654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg administered at 17.00 (5 p.m.)
Number of subjects: 30
Study 10635654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg administered at 20.00 (8 p.m.)
Number of subjects: 30
Study 8942397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil (25 mg orally)
Number of subjects: 12
Study 8942397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1972430 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched 'preterm' formula
Number of subjects: 424
Study 1972430 — intervention group
Group type: COMPARATOR
Intervention: Standard 'term' formula
Number of subjects: 424
Study 31221222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin as add-on to morphine
Number of subjects: 0
Study 31221222 — intervention group
Group type: COMPARATOR
Intervention: Control group (morphine only)
Number of subjects: 0
Study 28169875 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency
Number of subjects: 1571
Study 28169875 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 1571
Study 26359814 — intervention group
Group type: EXPERIMENTAL
Intervention: IR1W (830 nm, 100 mW, 5 J, 176 J/cm2, 50 s, 10 sessions)
Number of subjects: 78
Study 26359814 — intervention group
Group type: EXPERIMENTAL
Intervention: IR3W (830 nm, 100 mW, 5 J, 176 J/cm2, 50 s, 9 sessions)
Number of subjects: 78
Study 26359814 — intervention group
Group type: EXPERIMENTAL
Intervention: Red laser (685 nm, 35 mW, 2 J, 72 J/cm2, 58 s, 9 sessions)
Number of subjects: 78
Study 26359814 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 78
Study 26359814 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including CG)
Number of subjects: 78
Study 25001961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU intranasally)
Number of subjects: 60
Study 25001961 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 60
Study 21773714 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyherb (Tinospora cordifolia and Zingiber officinale based)
Number of subjects: 121
Study 21773714 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoherb (Semecarpus anacardium)
Number of subjects: 121
Study 21773714 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine sulfate (HCQS)
Number of subjects: 121
Study 21773714 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQS and Polyherb
Number of subjects: 121
Study 19331705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention combining nutrition information with increased availability of vegetables, fruits, and wholegrain bread
Number of subjects: 481
Study 19331705 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of folate from wholegrain bread
Number of subjects: 481
Study 17768058 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2g alpha-ketoglutaric acid and 720 mg 5-hydroxymethylfurfural/day (SANOPAL) from days 1 to 10
Number of subjects: 32
Study 15229713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation for everyone in Scandinavia
Number of subjects: 0
Study 15229713 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folate supplements for women of fertile age
Number of subjects: 0
Study 15229713 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral pill for people in risk groups
Number of subjects: 0
Study 15229713 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of vitamins and minerals
Number of subjects: 0
Study 15229713 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet
Number of subjects: 0
Study 12109935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (bupropion SR) 150mg twice daily
Number of subjects: 0
Study 12109935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (bupropion SR) 300mg/day
Number of subjects: 0
Study 12109935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (bupropion SR)
Number of subjects: 0
Study 12109935 — intervention group
Group type: COMPARATOR
Intervention: Nicotine transdermal patch
Number of subjects: 0
Study 9817266 — intervention group
Group type: EXPERIMENTAL
Intervention: CA10 (10 cycles of doxorubicin)
Number of subjects: 299
Study 9817266 — intervention group
Group type: COMPARATOR
Intervention: CA5 (5 cycles of doxorubicin)
Number of subjects: 299
Study 9817266 — intervention group
Group type: EXPERIMENTAL
Intervention: CA10 with moderate/high dose-volume cardiac RT
Number of subjects: 299
Study 9817266 — intervention group
Group type: EXPERIMENTAL
Intervention: CA5 with locoregional RT
Number of subjects: 299
Study 8176012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreens containing 2% or 5% oxybenzone
Number of subjects: 5
Study 8176012 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0% oxybenzone)
Number of subjects: 5
Study 8176012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreens containing 7% octyl dimethyl para‐aminobenzoic acid
Number of subjects: 5
Study 8176012 — intervention group
Group type: EXPERIMENTAL
Intervention: All tested formulations
Number of subjects: 5
Study 3582314 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a standard mixture of 22 different organic gases and vapors
Number of subjects: 62
Study 28834390 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target (TTT) strategy implementation
Number of subjects: 641
Study 27938358 — intervention group
Group type: EXPERIMENTAL
Intervention: pMDI BDP/FF 200/6 (two actuations bid)
Number of subjects: 376
Study 27938358 — intervention group
Group type: COMPARATOR
Intervention: BDP 100 μg (four actuations bid)
Number of subjects: 376
Study 26646404 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isoflurane
Number of subjects: 60
Study 26646404 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam and/or propofol
Number of subjects: 60
Study 23455860 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria-based reminder to remove the catheter
Number of subjects: 278
Study 23455860 — intervention group
Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 278
Study 20565044 — intervention group
Group type: EXPERIMENTAL
Intervention: Saint John's Wort Extract (antidepressant treatment)
Number of subjects: 30
Study 18223608 — intervention group
Group type: EXPERIMENTAL
Intervention: High Oleic Acid (HI OA) diet (PA = 1.7%, OA = 31.4%)
Number of subjects: 43
Study 18223608 — intervention group
Group type: EXPERIMENTAL
Intervention: High Palmitic Acid (HI PA) diet (PA = 16.8%, OA = 16.4%)
Number of subjects: 43
Study 19291124 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Proud! Be Responsible! intervention
Number of subjects: 1357
Study 19291124 — intervention group
Group type: COMPARATOR
Intervention: General health promotion program (control)
Number of subjects: 1357
Study 15752403 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of thermal indicator into the right atrium
Number of subjects: 50
Study 15752403 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of thermal indicator into the right ventricle
Number of subjects: 50
Study 11560559 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravesical MMC plus local hyperthermia (Group 1)
Number of subjects: 51
Study 11560559 — intervention group
Group type: COMPARATOR
Intervention: 20 mg MMC alone (Group 2)
Number of subjects: 51
Study 11560559 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intravesical MMC plus local hyperthermia (Group 3)
Number of subjects: 51
Study 11560559 — intervention group
Group type: COMPARATOR
Intervention: 40 mg MMC alone (Group 4)
Number of subjects: 51
Study 9623316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 3 x 5 mg in a suspension one day before surgery and 30 mg 3 and 8 hours after surgery, followed by 2 x 30 mg in suppositories until oral ingestion is possible
Number of subjects: 0
Study 9623316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7910488 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid with cimetidine
Number of subjects: 21
Study 7910488 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid with ranitidine
Number of subjects: 21
Study 7910488 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid with nizatidine
Number of subjects: 21
Study 7910488 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid with famotidine
Number of subjects: 21
Study 7910488 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid with all agents tested
Number of subjects: 21
Study 3294618 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitoxin
Number of subjects: 13
Study 3294618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31664624 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM)
Number of subjects: 54
Study 31664624 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 54
Study 31664624 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Least Squares Discriminant Analysis (PLS-DA)
Number of subjects: 54
Study 31664624 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR)
Number of subjects: 54
Study 30518583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative network meta-analysis (NMA) of drug treatments for postmenopausal osteoporosis
Number of subjects: 0
Study 30518583 — intervention group
Group type: COMPARATOR
Intervention: Practice guidelines recommendations
Number of subjects: 0
Study 26643027 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious support expression
Number of subjects: 0
Study 26643027 — intervention group
Group type: COMPARATOR
Intervention: General emotional support messages
Number of subjects: 0
Study 25188297 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg
Number of subjects: 510
Study 25188297 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg
Number of subjects: 510
Study 25188297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 22115944 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinosad and milbemycin oxime combination (30-45 mg/kg spinosad; 0.5-0.75 mg/kg MO)
Number of subjects: 20